Mednet Logo

What would be your next line of treatment for disease control in a pediatric patient with metastatic hepatocellular carcinoma in partial response after multiple therapies?

The patient already received PLADO+sorafenib, Y90, and Atezolizumab/Bevacizumab complicated by recurrent episodes of bleeding from esophageal varices. Metastases have resolved and primary tumor has shown partial response to prior treatment.
3 Answers
Mednet Member
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · UCSF School of Medicine
Answered on

Dear Dr. @Dr. First Last,

Does the patient have an underlying hepatopathy (guessing yes, given the presence of varices)? And how old is the patient? Also - what was the AFP at diagnosis and what is it now? And what is the underlying liver function like?
Final question - has the tumor been sequenced ...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · FibroFighters Foundation
Answered on

Hello Dr. @Dr. First Last,

Of course, I agree with Dr. @Dr. First Last about getting more information - for me, the main question is: Is this fibrolamellar carcinoma (FLC)? Adolescent and otherwise healthy and lack of underlying liver disease (and usually normal AFP) are the hallmark of FLC. We need...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · FibroFighters Foundation
Answered on

Gemcitabine (500 mg/m² IV) + oxaliplatin (50 mg/m² IV) every 2 weeks + lenvatinib 4 mg PO daily, or nivolumab (2 mg/kg IV) + gemcitabine (500 mg/m² IV) every 2 weeks + lenvatinib 4 mg PO daily.

Join for free or sign in to see the full answer